{"hands_on_practices": [{"introduction": "The journey of a liquid biopsy analysis begins with the successful isolation of circulating cell-free DNA (cfDNA) from a patient's plasma. The total amount of recovered cfDNA is a critical parameter, as it dictates the feasibility and sensitivity of all subsequent genomic assays. This foundational exercise [@problem_id:4316864] walks you through the essential calculation of cfDNA yield, connecting the initial sample volume, intrinsic cfDNA concentration, and the efficiency of the lab's extraction protocol.", "problem": "A clinical oncology laboratory is evaluating the recovery of circulating cell-free deoxyribonucleic acid (cfDNA) from plasma for downstream genomic diagnostics in precision medicine. The laboratory draws venous blood from a patient with metastatic carcinoma, processes the sample to obtain plasma, and immediately performs cfDNA extraction using a standardized silica membrane method. Assume the following scientifically grounded definitions and facts:\n\n- Concentration is defined as mass per unit volume, so if $m$ is the cfDNA mass present in plasma and $V$ is the plasma volume, then the cfDNA concentration $C$ satisfies $C = \\frac{m}{V}$.\n- The recovery efficiency of an extraction method is defined as the fraction of input cfDNA mass that is recovered, so if $m_{\\mathrm{rec}}$ is the recovered cfDNA mass and $m$ is the input cfDNA mass present in the plasma processed, then extraction efficiency $E$ satisfies $E = \\frac{m_{\\mathrm{rec}}}{m}$.\n- The plasma is homogeneous with respect to cfDNA distribution, and pre-analytical handling does not change $V$, $C$, or $E$.\n\nThe laboratory processes $V = 10\\,\\mathrm{mL}$ of plasma with cfDNA concentration $C = 15\\,\\mathrm{ng/mL}$ using an extraction protocol whose empirically validated efficiency is $E = 0.70$.\n\nUsing only the above definitions and facts, derive the recovered cfDNA mass $m_{\\mathrm{rec}}$ in nanograms. Express your final answer in ng. No rounding is required; report the exact value.", "solution": "The problem is valid as it is scientifically grounded in the principles of molecular diagnostics, is well-posed with sufficient and consistent data, and is expressed in objective, formal language. The provided values for plasma volume, cfDNA concentration, and extraction efficiency are realistic for a clinical laboratory setting.\n\nThe objective is to determine the recovered mass of cfDNA, denoted as $m_{\\mathrm{rec}}$, from the given parameters. The solution requires a two-step calculation based on the provided definitions.\n\nFirst, we must determine the total mass of cfDNA, $m$, present in the initial plasma sample. The problem defines the concentration, $C$, as the mass per unit volume, $V$:\n$$C = \\frac{m}{V}$$\nThe given values are the plasma volume, $V = 10\\,\\mathrm{mL}$, and the cfDNA concentration, $C = 15\\,\\mathrm{ng/mL}$. We can rearrange the definition of concentration to solve for the total mass, $m$:\n$$m = C \\times V$$\nSubstituting the provided values into this equation yields:\n$$m = (15\\,\\mathrm{ng/mL}) \\times (10\\,\\mathrm{mL})$$\nThe units of volume ($\\mathrm{mL}$) cancel, resulting in the total mass in nanograms:\n$$m = 150\\,\\mathrm{ng}$$\nThis value, $m = 150\\,\\mathrm{ng}$, represents the total input cfDNA mass available for extraction.\n\nSecond, we calculate the recovered mass, $m_{\\mathrm{rec}}$, using the definition of extraction efficiency, $E$. The efficiency is defined as the fraction of the input mass that is recovered:\n$$E = \\frac{m_{\\mathrm{rec}}}{m}$$\nThe problem states that the extraction efficiency is $E = 0.70$. We can rearrange this equation to solve for the recovered mass, $m_{\\mathrm{rec}}$:\n$$m_{\\mathrm{rec}} = E \\times m$$\nNow, we substitute the known values for efficiency, $E$, and the previously calculated total mass, $m$:\n$$m_{\\mathrm{rec}} = 0.70 \\times 150\\,\\mathrm{ng}$$\nPerforming the multiplication gives the final result for the recovered cfDNA mass:\n$$m_{\\mathrm{rec}} = 105\\,\\mathrm{ng}$$\nThus, the mass of cfDNA recovered from the plasma sample is $105\\,\\mathrm{ng}$. This is an exact value as requested by the problem statement.", "answer": "$$\\boxed{105}$$", "id": "4316864"}, {"introduction": "Once cfDNA is sequenced, a key objective is to quantify the proportion of fragments originating from the tumor, known as the tumor fraction ($f_{tumor}$). This value serves as a dynamic biomarker for tumor burden. This practice [@problem_id:4316822] delves into the core principle linking the variant allele frequency (VAF) of a heterozygous somatic mutation to the underlying tumor fraction, demonstrating why the expected VAF is approximately $f_{tumor}/2$ under diploid conditions and how combining information from multiple mutations provides a more robust estimate.", "problem": "A precision oncology laboratory uses targeted next-generation sequencing (NGS) on plasma cell-free DNA (cfDNA) to quantify the variant allele frequency (VAF) of somatic mutations for estimating the circulating tumor DNA (ctDNA) fraction, denoted by $f_{tumor} \\in (0,1)$. Consider three independent, clonal, heterozygous somatic point mutations that reside in diploid regions without copy-number alterations or allelic imbalance. Assume no subclonality, no tumor heterogeneity at these loci, and no assay bias, so that each tumor-derived diploid genome contributes exactly one mutated allele and one reference allele at each locus, while normal diploid genomes contribute two reference alleles.\n\nBy definition of mixture and allele counting, under these conditions the expected VAF for a heterozygous mutation equals the proportion of mutated alleles among all alleles in the cfDNA mixture. Using first principles of mixture composition and allele counting, argue that the expected VAF at each such locus equals $f_{tumor}/2$. Suppose the observed VAFs for the three loci are $0.030$, $0.028$, and $0.034$. Assume each observed VAF, denoted $v_i$, is an independent, unbiased measurement of its expectation with equal Gaussian measurement variance arising from similar high read depths.\n\nUsing these assumptions, derive from first principles a maximum likelihood estimator for $f_{tumor}$ based on the three observations, and then compute its numerical value using the given data. Express $f_{tumor}$ as a unitless decimal fraction and round your final answer to four significant figures.", "solution": "The starting point is the mixture model and allele counting under diploidy. In plasma cell-free DNA (cfDNA), a fraction $f_{tumor}$ of DNA fragments arise from tumor cells and a fraction $1 - f_{tumor}$ from normal cells. At a heterozygous somatic locus that is clonal in the tumor and diploid in both tumor and normal, each tumor-derived diploid genome contributes one mutated allele and one reference allele, while each normal-derived diploid genome contributes two reference alleles. Therefore, among all alleles in the mixture, the expected fraction of mutated alleles is the ratio of mutated alleles to total alleles:\n$$\n\\text{Expected mutated-allele fraction} = \\frac{f_{tumor} \\times 1 + (1 - f_{tumor}) \\times 0}{2} = \\frac{f_{tumor}}{2}.\n$$\nThis equals the expected variant allele frequency (VAF) at such a locus. Let the observed VAFs be $v_1, v_2, v_3$, and suppose\n$$\nv_i = \\frac{f_{tumor}}{2} + \\epsilon_i, \\quad \\epsilon_i \\sim \\mathcal{N}(0,\\sigma^{2}), \\quad i \\in \\{1,2,3\\},\n$$\nwith independent and identically distributed Gaussian noise of equal variance due to similar high read depths.\n\nUnder this homoscedastic Gaussian model, the log-likelihood for $f_{tumor}$ (up to an additive constant) is\n$$\n\\ell(f_{tumor}) = -\\frac{1}{2\\sigma^{2}} \\sum_{i=1}^{3} \\left(v_i - \\frac{f_{tumor}}{2}\\right)^{2}.\n$$\nMaximizing $\\ell(f_{tumor})$ is equivalent to minimizing the sum of squared residuals\n$$\nS(f_{tumor}) = \\sum_{i=1}^{3} \\left(v_i - \\frac{f_{tumor}}{2}\\right)^{2}.\n$$\nDifferentiate $S(f_{tumor})$ with respect to $f_{tumor}$ and set the derivative to zero:\n$$\n\\frac{dS}{df_{tumor}} = \\sum_{i=1}^{3} 2\\left(v_i - \\frac{f_{tumor}}{2}\\right)\\left(-\\frac{1}{2}\\right) = -\\sum_{i=1}^{3} \\left(v_i - \\frac{f_{tumor}}{2}\\right) = 0.\n$$\nTherefore,\n$$\n\\sum_{i=1}^{3} v_i - \\frac{3}{2} f_{tumor} = 0 \\quad \\Longrightarrow \\quad f_{tumor} = \\frac{2}{3} \\sum_{i=1}^{3} v_i = 2 \\,\\bar{v},\n$$\nwhere $\\bar{v}$ is the sample mean of the observed VAFs. With $v_1 = 0.030$, $v_2 = 0.028$, and $v_3 = 0.034$,\n$$\n\\bar{v} = \\frac{0.030 + 0.028 + 0.034}{3} = \\frac{0.092}{3} = 0.030\\overline{6}.\n$$\nHence,\n$$\n\\hat{f}_{tumor} = 2 \\times 0.030\\overline{6} = 0.061\\overline{3}.\n$$\nRounded to four significant figures as a unitless decimal fraction,\n$$\n\\hat{f}_{tumor} = 0.06133.\n$$", "answer": "$$\\boxed{0.06133}$$", "id": "4316822"}, {"introduction": "A positive result from a highly sensitive liquid biopsy assay does not automatically confirm the presence of cancer; its clinical meaning is a matter of probability. The reliability of a positive finding is quantified by the Positive Predictive Value (PPV), which is critically dependent not only on the assay's sensitivity and specificity but also on the pre-test probability, or prevalence, of the mutation in the patient population. This exercise [@problem_id:4316803] applies the fundamental logic of Bayes' theorem to determine the PPV, providing a crucial lesson in the robust interpretation of diagnostic test results.", "problem": "An oncology molecular diagnostics laboratory implements a circulating tumor DNA (ctDNA) liquid biopsy to detect a therapeutically actionable single-nucleotide variant in advanced solid tumors. For a specific tumor type and gene target in this clinical context, the laboratory has analytically validated the test performance and estimates the following operating characteristics in routine practice: the clinical sensitivity is $0.85$, the clinical specificity is $0.99$, and the pretest probability of the target mutation in the tested population (mutation prevalence) is $0.05$. A patient’s ctDNA liquid biopsy returns a positive result for the mutation. Starting from the definitions of sensitivity, specificity, and prevalence, and invoking Bayes’ theorem as the foundational probabilistic rule connecting conditional and marginal probabilities, derive the expression for the posterior probability that the patient truly harbors the mutation given a positive test result, which is the positive predictive value $PPV = \\mathbb{P}(\\text{mutation} \\mid \\text{test positive})$. Then evaluate this expression for the given parameters. Express the final probability as a decimal and round your answer to four significant figures.", "solution": "To solve this problem, we will use Bayes' theorem to calculate the Positive Predictive Value (PPV), which is the probability that a patient truly has the mutation given a positive test result, or $\\mathbb{P}(\\text{Mutation} \\mid \\text{Positive Test})$.\n\nFirst, let's define the events based on the problem statement:\n*   $M$: The patient has the mutation.\n*   $M^c$: The patient does not have the mutation.\n*   $T^+$: The test result is positive.\n*   $T^-$: The test result is negative.\n\nThe given parameters can be expressed as probabilities:\n*   Prevalence, $\\mathbb{P}(M) = 0.05$. Therefore, $\\mathbb{P}(M^c) = 1 - 0.05 = 0.95$.\n*   Sensitivity, $\\mathbb{P}(T^+ \\mid M) = 0.85$.\n*   Specificity, $\\mathbb{P}(T^- \\mid M^c) = 0.99$.\n\nFrom the specificity, we can derive the false positive rate (FPR), which is the probability of a positive test in a patient without the mutation:\n$$ \\text{FPR} = \\mathbb{P}(T^+ \\mid M^c) = 1 - \\text{Specificity} = 1 - 0.99 = 0.01 $$\n\nBayes' theorem for the PPV is:\n$$ \\text{PPV} = \\mathbb{P}(M \\mid T^+) = \\frac{\\mathbb{P}(T^+ \\mid M) \\mathbb{P}(M)}{\\mathbb{P}(T^+)} $$\n\nThe denominator, $\\mathbb{P}(T^+)$, is the total probability of a positive test, which can be found using the law of total probability:\n$$ \\mathbb{P}(T^+) = \\mathbb{P}(T^+ \\mid M)\\mathbb{P}(M) + \\mathbb{P}(T^+ \\mid M^c)\\mathbb{P}(M^c) $$\n\nSubstituting this into the Bayes' theorem formula gives the full expression for PPV in terms of sensitivity (Se), specificity (Sp), and prevalence (Prev):\n$$ \\text{PPV} = \\frac{\\text{Se} \\times \\text{Prev}}{(\\text{Se} \\times \\text{Prev}) + ((1 - \\text{Sp}) \\times (1 - \\text{Prev}))} $$\n\nNow, we can plug in the given numerical values:\n$$ \\text{PPV} = \\frac{0.85 \\times 0.05}{(0.85 \\times 0.05) + ((1 - 0.99) \\times (1 - 0.05))} $$\n$$ \\text{PPV} = \\frac{0.0425}{0.0425 + (0.01 \\times 0.95)} $$\n$$ \\text{PPV} = \\frac{0.0425}{0.0425 + 0.0095} $$\n$$ \\text{PPV} = \\frac{0.0425}{0.0520} \\approx 0.81730769... $$\n\nRounding the final answer to four significant figures, we get:\n$$ \\text{PPV} \\approx 0.8173 $$\nThis means there is an 81.73% probability that a patient with a positive test result truly has the mutation. This calculation underscores the critical dependence of PPV on the prevalence of the condition in the tested population.", "answer": "$$\\boxed{0.8173}$$", "id": "4316803"}]}